Bank Julius Baer & Co. Ltd, Zurich Arbutus Biopharma Corp Transaction History

Bank Julius Baer & Co. Ltd, Zurich

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$2.42 - $3.98 $18,876 - $31,044	-7,800 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$3.11 - $4.61 $4,043 - $5,993	1,300 Added 20.0%	7,800 $30,000
Q3 2021 Nov 12, 2021	SELL	$2.65 - $4.62 $267 - $466	-101 Reduced 1.53%	6,500 $28,000
Q2 2021 Jul 23, 2021	BUY	$2.5 - $3.51 $252 - $354	101 Added 1.55%	6,601 $20,000
Q1 2021 May 10, 2021	BUY	$3.14 - $4.84 $65 - $101	21 Added 0.32%	6,500 $22,000
Q4 2020 Feb 24, 2021	SELL	$2.76 - $4.97 $57 - $104	-21 Reduced 0.32%	6,479 $23,000
Q4 2020 Feb 12, 2021	BUY	$2.76 - $4.97 $13,799 - $24,850	5,000 Added 333.33%	6,500 $23,000
Q3 2020 Nov 10, 2020	BUY	$1.75 - $6.2 $2,625 - $9,300	1,500 New	1,500 $5,000

138

95.5M

3.44M

377K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $577M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.